APA (7th ed.) Citation

L, A., J, F., & E, C. (2021). Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated. Endocrine, 72(1), 216. https://doi.org/10.1007/s12020-020-02557-1

Chicago Style (17th ed.) Citation

L, Andereggen, Frey J, and Christ E. "Long-term IGF-1 Monitoring in Prolactinoma Patients Treated with Cabergoline Might Not Be Indicated." Endocrine 72, no. 1 (2021): 216. https://doi.org/10.1007/s12020-020-02557-1.

MLA (9th ed.) Citation

L, Andereggen, et al. "Long-term IGF-1 Monitoring in Prolactinoma Patients Treated with Cabergoline Might Not Be Indicated." Endocrine, vol. 72, no. 1, 2021, p. 216, https://doi.org/10.1007/s12020-020-02557-1.